Sirdalud 30CPR 28CPR RIV 6mg
Active tizanidine hydrochloride
centrally acting muscle relaxation therapy group
Product Type Ethical Regime SSN MAKES NO
Class C Type RR Recipe - Repeat
Form Farm. TABLETS BLISTER
container Validity Date Commerc 36 months. Price
ATC M03BX02
The product contains no gluten, gluten
Manufacturer Novartis Farma SpA
NAME
Sirdalud
Pharmacotherapeutic
centrally acting muscle relaxation.
ACTIVE
Tablets 2 mg: 2.29 mg tizanidine hydrochloride equivalent to 2.00 mg tizani
dynamic basis. 4 mg tablets: 4.58 mg tizanidine hydrochloride
m of 4.00 g of tizanidine base. 6 mg tablets: 6.86 mg tizanidine hydrochloride
re pa to 6.00 mg tizanidine base.
EXCIPIENTS
colloidal anhydrous silica, stearic acid, cellulose Microcrystalline
anhydrous lactose. INDICATIONS
painful muscle spasms: static and functional disorders associated with
of the spine (cervical and lumbar arthrosis syndromes, tor
cicollo, backaches, etc..) Following surgery (
herniated disc, arthritis of the hip, etc...) Spasticity 'subsequent to initial neurological
messy: eg. multiple sclerosis, chronic myelopathy, diseases of
Egenera spinal cord, cerebral vascular accidents.
CONTRAINDICATIONS / EFF.SECONDAR
significant impairment 'liver. The concurrent use of tizanidine
itante with strong inhibitors of cytochrome P1A2 as fluvial
xamina or ciprofloxacin and 'contra-indicated. Hypersensitivity 'to tizan
Idina or any of the excipients.
DOSAGE
painful muscle spasms: 2 to 4 mg two to three times of '. In severe cases
we recommend supplementation with 1 tablet of
2 or 4 mg before bedtime. Spasticity 'disorders resulting from neur
ology: The dosage should be adjusted to the needs'
the individual patient. The initial dose should not exceed 6 mg daily in three divided doses
. Then gradually increase to 2-4 g m
every three to six days. In most patients the answer you
optimal therapeutic action is generally achieved with a dose of 12-24 mg
divided into 3 or 4 daily doses. It is recommended that n
pass on the maximum daily dose of 36 mg. During
chin is recommended to identify whether
one can make a reduction in dosage. Use in children: the available data are limited and therefore not
dosing is recommended for children. Use in an
older people: the available data are limited. Pharmacokinetic data
ican ind that in some cases in the elderly renal clearance can '
be significantly reduced. We therefore recommend caution in somminis
contraries the drug in the elderly.
CONSERVATION
None.
WARNINGS
inhibitors of cytochromes P: Concomitant use of tizanidine with
ibitori in cytochrome P1A2 is not 'recommended. Hypotension:
during the treatment with tizanidine and as a result of interaction with them g
inhibitors of cytochrome P1A2 and / or antihypertensive drugs, can '
onset hypotension. Have also been reported serious events
of hypotension with loss of consciousness and circulatory collapse. Sind
rome interruption: after abrupt cessation of tizanidine in
case it has been used chronically, and / or high daily doses
ages, and / or concurrently with antihypertensive drugs, were observed
you rebound hypertension and tachycardia . In extreme cases, the hypertensive
one rebound could lead to stroke. Tizan
Idina should not be stopped abruptly but gradually.
Hepatic impairment: cases have been reported to alter function
ata 'liver in association with treatment with tizanidine
, although these events rarely occur at doses up to
12 mg / day. Therefore, in patients treated with doses equal
me more than 12 mg / day or in the case of patients with clinical symptoms of liver dysfunction
me (of unknown origin
such as nausea, anorexia, asthenia), it is recommended that assays of one function evaluation
' hepatic monthly for the first 4 months of tera
pious. Treatment should be discontinued if the serum levels of SGOT and SGPT are constantly
tripled compared to the upper limit of normal range and
'. Renal impairment: in patients with insufficient
renal failure (creatinine clearance < 25 ml/min) si raccomanda
initiating therapy with 2 mg once daily. The dosage goes
ument gradually as tolerated 'and effectiveness, aum
entando the single dose before changing the frequency of administration
ion. cardiovascular and coronary insufficiency: ela
we recommend caution in patients with severe cardiovascular and renal c
oronarica. If it is establishing in these patients treated with the drug will
'should be conducted at regular intervals, the normal
the diagnostic laboratory along with a regular electrocardiogram monitoring
. In these patients, however, the dosage of
maco to be properly adjusted. The product contains milk
Osio, therefore not suitable for patients with galactose intolerance, severe lactase deficiency
, or galactose malabsorption
glucose-galactose.
INTERACTIONS
inhibitors of cytochromes P: Concomitant use of medications known to
ibizione of the activity in the 'cytochrome P1A2 can' raise the level of asthma
pl of tizanidine. Concomitant use of tizanidine with fluvoxami
na or ciprofloxacin, both potent inhibitors of human cytochrome P450 1A2
mo, and 'contra-indicated. Concomitant use of tizanidine and ciprofloxacin with f
luvoxamina results in an increase of tizani
dynamic of fluvoxamine by 33 times and 10 times by cip
rofloxacina. This 'can cause hypertension and clinically important
prolonged, drowsiness, dizziness, and reduction of skill' psychomotor
ia. It 's not recommended for concomitant use of tizanidine with other ini
BITOR cytochrome P1A2, as some antiarrhythmics (amiodarone, mexile
tina, propafenone), cimetidine, some fluoroquinolones (enoxacin, pef
loxacina, norfloxacin), rofecoxib, oral contraceptives, and ticlopidine
. The increased plasma levels of tizanidine may lead to overdosing s
intomi as prolongation of the QT (c). An
tiipertensivi: Concomitant use of tizanidine with antihypertensives, the
nclusi diuretics, can 'give
occasionally hypotension and bradycardia. In some patients, after abrupt cessation of tizanidine, when s
omministrata with antihypertensive drugs, were observed
sion rebound hypertension and tachycardia. In extreme cases of hypertension rim
jump could lead to stroke. Others: tranqu
illanti and alcohol may enhance the sedative action of tizanidine.
SIDE EFFECTS Side effects are listed according to frequency using the
following convention: Very common (> = 1 / 10), common (> = 1 / 100, < 1/
10), uncommon (> = 1 / 1000, < 1/100); rari (> = 1/10.000, < 1/1000); mo
lto rare (< 1/10.000), compresi casi isolati. >> Psychiatric Disorders.
Rare: hallucinations, insomnia, sleep disorders.>>
nervous system disorders. Common: drowsiness, dizziness.>> heart disease.
Co muni: bradycardia .>> vascular disorders. Common: Hypotension.>> Altera
tions of the gastrointestinal tract. Common: dry mouth;
Rare: nausea, gastrointestinal upset. >> Hepatobiliary disorders. Mol
to rare: hepatitis, liver failure. >> M
Uscoli skeletal disorders and connective tissue. Rare: muscular weakness. >>
General disorders and administration site.
common: fatigue. >> Investigations. Common: blood pressure decrease
; Rare: increased transaminases. At low doses, such as those
and recommended for the resolution of the painful muscle spasms, are
nolenza, fatigue, dizziness, dry mouth, drop in blood pressure
, nausea, gastrointestinal disorders and increased transaction
Minasi were reported as media entities' and transient. At doses
more 'high, recommended for the treatment of spasticity', the eff ects
events reported at low doses are more 'and more often' pr
onunciati, but rarely severe enough to require discontinuation of the treatment
. Where increased transaminases not
NOT report the standard by 4-6 weeks will be 'appropriate suspending
and treatment. In addition, the following effects may occur inde
siderite: hypotension, bradycardia, muscle weakness, insomnia dist
urbi of sleep, hallucinations, hepatitis. Withdrawal syndrome:
after abrupt cessation of tizanidine, in case it has been used
PROVIDING chronically and / or high daily doses, and / or concurrently with
antihypertensive drugs, were observed rebound hypertension
oe tachycardia. In extreme cases, the rebound hypertension may
s fociare in stroke.
PREGNANCY AND LACTATION
The tizanidine has not shown teratogenic effects in rats and with
Iglio. Since 'no controlled studies have been conducted in women gr
greed, tizanidine should not be administered during pregnancy
za except in cases in which the benefit is' clearly outweighs the potential res
mark. Although Animal studies indicate that only minute quantities
ime 'of tizanidine is excreted in breast milk, the Tiza
Nidina should not be used during lactation.
0 comments:
Post a Comment